GreenGene F, Next-gen Hemophilia A Treatment, Approved in China

GreenGene F, Next-gen Hemophilia A Treatment, Approved in China

303250

GreenGene F, Next-gen Hemophilia A Treatment, Approved in China

GreenGene F (beroctocog alfa), a lab-made version of coagulation factor VIII, has been approved by regulators in China for the control and prevention, or prophylaxis, of bleeding episodes associated with hemophilia A, the therapy’s developer, GC Pharma,  announced. GreenGene F will be available in China in the first half of 2022, and marketed in collaboration with the company’s affiliate, GC China. “The approval of GreenGene F in China marks an important milestone for GC Pharma and…

You must be logged in to read/download the full post.